Thursday, November 8, 2012
Publication and contact
acid bacteria for treating inflammatory bowel disease (IBD)
acid bacteria could be useful for treating IBD. Two food-grade strains of
lactic acid bacteria were engineered to express the protease inhibitor
elafin, which is downregulated in the colons of patients with IBD. In a mouse
model of chemically induced colitis, oral delivery of the engineered
bacterial strain restored intestinal homeostasis and decreased gut
inflammation compared with wild-type bacteria. Next steps include evaluating
the safety of the engineered bacteria.
ViThera Pharmaceuticals Inc.
is developing the engineered bacteria for use in IBD (see IBD's bacteria
cafeteria, page 8).
Published online Nov. 8, 2012
Patented; licensed to
Motta, J.-P. et al. Sci.
published online Oct. 31, 2012;
Contact: Nathalie Vergnolle,
Institut National de
la Santé et de la Recherche
Médicale (INSERM), Toulouse, France
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]